Mersana Therapeutics

Search
  • About
    • Mission & Vision
    • Executive Team
    • Board of Directors
    • Scientific Advisory Board
    • Partnering
  • Pipeline
    • Overview
    • Upifitamab Rilsodotin
  • Technology Platforms
    • About ADCs
    • DolaLock Technology
    • Dolaflexin
    • Dolasynthen
    • Immunosynthen
  • Publications
  • Investors & Media
    • Overview
    • Stock Information
    • Analyst Coverage
    • SEC Filings
    • Press Releases
    • Events & Presentations
    • Annual Meeting
    • Corporate Governance
    • Investor FAQs
    • Contact Us
  • Careers
    • Culture
    • Benefits
    • Open Positions
  • Contact
Dolasynthen, Publications, XMT-1660

Anti-tumor effect of XMT-1660, a B7-H4 targeting antibody drug conjugate, in an unselected panel of patient derived xenograft models of breast cancer

April, 2022

Dolasynthen, Publications

Site Specific Dolasynthen ADCs demonstrate consistent exposure across a wide range of drug-to-antibody ratios

October, 2021

Dolasynthen, Platform, Publications, XMT-1660

XMT-1660, a B7-H4-Targeted Dolasynthen Antibody-Drug Conjugate for the Treatment of Breast Cancer

April, 2021

Dolasynthen, Publications, XMT-1592

XMT-1592, a Site-Specific Dolasynthen-Based NaPi2b-Targeted Antibody-Drug Conjugate for the Treatment of Ovarian Cancer and Lung Adenocarcinoma

June, 2020

Dolaflexin, DolaLock, Dolasynthen, Immunosynthen, Publications, UpRi (XMT-1536)

Mersana’s Innovative ADC Platforms – World ADC Summit 2019

October 2019

DolaLock, Dolasynthen, Publications

Dolasynthen: A Novel, Homogeneous Auristatin F Hydroxypropyl Amide Antibody-Drug Conjugate Platform

April 2019

DolaLock, Dolasynthen, Publications

Discovery of the novel, homogeneous payload platform Dolasynthen for Antibody-Drug Conjugates

November 2018

© 2022 Mersana Therapeutics, All Rights Reserved. Privacy Policy | Terms of Use
linkedin icon twitter icon facebook icon instagram icon
logo
  • About
    • Mission & Vision
    • Executive Team
    • Board of Directors
    • Scientific Advisory Board
    • Partnering
  • Pipeline
    • Overview
    • Upifitamab Rilsodotin
  • Technology Platforms
    • About ADCs
    • DolaLock Technology
    • Dolaflexin
    • Dolasynthen
    • Immunosynthen
  • Publications
  • Investors & Media
    • Overview
    • Stock Information
    • Analyst Coverage
    • SEC Filings
    • Press Releases
    • Events & Presentations
    • Annual Meeting
    • Corporate Governance
    • Investor FAQs
    • Contact Us
  • Careers
    • Culture
    • Benefits
    • Open Positions
  • Contact